Lightcalls.com

A derivative of vitamin A called fe...

A derivative of vitamin A called fenretinide (not available as a supplement) may retain young women with early breast cancer from developing the disease any further.

According to Reuter Health, Dr Alberto Costa of the European Institute of Oncology in Milan reported at the inferior European Breast Cancer Conference that fenretinide can hinder the growth of a inferior tumor in young women with breast cancer. The consideration showed that because the compromise works with estrogen to stop up tumor growth, it is merely effective in premenopausal women.

Other Articles

-Morphotek will collaborat...
-Eksigent Technologies nam...
-The benefits of outsourci...
-Sartorius Corporation ...
-In our previous column, w...
-Efoora appointed Michael ...
-Affymax appointed Anne-Ma...
-Traditionally, continuous...
-New Brunswick Scientific ...
-The German-American firm ...
-Don G. Burstyn, formerly ...
-American patients are mor...
-Summary Prior to va...
-BioPharm Editorial Adviso...
-Australia agreed to spend...
-The Biotechnology Industr...
-Ambion, The RNA Company i...
-Therapies based on living...
-A recent survey found tha...
-ViroLogic will acquire Ac...
-Cardinal Health named Joh...
-One of the greatest chall...
-As the president of a sma...
-Sweden-based Biovitrum wi...
-Nanogen appointed David L...
-The Experion Process Know...
-Although biomedical resea...
-The Supreme Court of Cana...
-Netherlands-based DSM Bio...
-David A. Smoller joined S...
-A few months ago, I wrote...
-Panacos Pharmaceuticals w...
-Karen K. Vaccaro will res...
-Acceleron Pharma appointe...
-Two quarterly meetings of...
-Illinois-based Abbot Labo...
-FKI Logistics announced t...
-The following corrections...
-It its widest definition,...
-UK-based Xcellsyz will li...
-Andrew P. Aromando joined...
-Invitrogen's comprehensiv...
-Last month, we described ...
-The Swiss life sciences c...
-Protein Design Labs (PDL)...
-Model It HNMR, the newest...
-Tech transfer, like chang...
-QLT and Atrix Laboratorie...
-Dendreon announced Christ...
-Baxter Pharmaceutical Sol...
-The biopharmaceutical ind...
-GlaxoSmithKline announced...
-Montreal-based Caprion Ph...
-Xenova Group recently ann...
-Cole-Parmer's new 192-pag...
-Over the last decade ther...
-Benchmark your facility p...
-As biotechnology organiza...
-Frederick D. Sancillo, fo...
-Insmed acquired a recombi...
-Baxter Pharmaceutical Sol...
-Model It HNMR, the newest...
-DA's regulation 21 CFR Pa...
-Robert P. Ryan joined Ath...
-A new report from Busines...
-Biotest offers a complete...
-Swagelok offers a brochur...
-Partnering is a global ph...
-Human Genome Sciences CEO...
-Shorten the process devel...
-The licensure of biotechn...
-Rodger Currie joined Amge...
-The GEA Filtration Model ...
-A multi-channel chemistry...
-From June 6-9, San Franci...
-Skanska USA Building Inc....
-New Brunswick Scientific'...
-AVI BioPharma appointed P...
-Ambion, The RNA Company, ...
-"If you want to be a...
-Xcellerex appointed Susan...
-Researchers identified th...
-Cool Spring Business Park...
-In October 2003, Shenzhen...
-Laureate Pharma appointed...
-After a 6-5 vote by Calif...
-QSourcing, a service of Q...
-The recent discovery of &...
-Affymax added Douglas L. ...
-USDA recently approved tw...
-BioPharm International is...
-Serologicals has released...
-This document by Shenzhen...
-Robert Bronstein joined A...
-Gloucester Gains Fujisawa...
-With more than 30 years o...
-Pall's SUPRAdisc II depth...
-In today's competitive ma...
-Protein Design Labs repor...
-Charles A. Rice will repl...
-AstraZeneca's Faslodex (f...